Zydus Cadila gets final USFDA approval for Ranitidine HcI injection

25 Feb 2013 Evaluate

Zydus Cadila has received the final approval from the USFDA to market Ranitidine Hcl injection 25 mg/ml. Used in the treatment of peptic ulcers, gastritis and gastroesophageal reflux disease (GERD), Ranitidine Hcl falls in the anti-secretory segment.

The estimated sales in 2012 as per IMS for Ranitidine Hcl injection was $5.4 million. The group now has 76 approvals and has so far filed 172 ANDAs since the commencement of the filing process in FY 2003-04.

Flagship company of Zydus Cadila Group, it focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.

Zydus Lifesciences Share Price

1001.15 -22.45 (-2.19%)
31-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1462.50
Dr. Reddys Lab 5784.50
Cipla 1451.25
Zydus Lifesciences 1001.15
Lupin 1587.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.